Activaero GmbH, a Gemuenden/Wohra, Germany developer of controlled breathing inhalation devices, has closed a further €5.0m (approximately $6.8m) financing round.
The round was led by LSP Life Sciences Partners, which committed € 3.5m, with participation from existing investors BioMedPartners AG, VI Partners AG, Abalis Finance AG, Vesalius Biocapital I SICAR S.A., MedVenture Partners GmbH and existing shareholders, which contributed further €1.5m.
Activaero intends to use the funds to further develop its proprietary pulmonary drug delivery technology and to establish further clinical activities.
In conjunction with the financing, Jörg Neermann, Partner at LSP, will represent LSP in the company’s supervisory board.
Led by founder and CEO Gerhard Scheuch, Activaero designs controlled breathing drug delivery technologies that are designed to maximize the efficiency and precision of inhaled drugs and enable safer and effective options for inhaled treatments of respiratory diseases.
The company is also located in Munich (Germany) and Dublin, Ohio (USA).